Olverembatinib Sales Surge 80.6% to $62.2M, Powering Ascentage Pharma's 2025 Results
AAPG sits 27% above its 52-week low of $17.555 on light trading volume (0.2× avg).
Summary
Ascentage Pharma reported strong unaudited full-year 2025 financial results, highlighted by an 80.6% increase in Olverembatinib sales to US$62.2 million, driven by its inclusion in China's NRDL. The company also successfully launched Lisaftoclax in China in July 2025, marking it as the first Bcl-2 inhibitor to receive conditional approval for CLL/SLL in the region. Additionally, Ascentage Pharma provided positive updates on its late-stage pipeline, with three global registrational Phase III trials underway for Olverembatinib and ongoing global Phase III trials for Lisaftoclax. These commercial and clinical advancements indicate significant progress in the company's mission to deliver innovative cancer therapies, which is a material positive for the stock.
At the time of this announcement, AAPG was trading at $22.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $17.56 to $48.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.